A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Basic science
Enrollment
8actual
Sites
1
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-04 | actual | When the study began enrolling |
| Primary completion | 2025-07-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-14 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Male Volunteers
Interventions
- Drug: [14C] PF-07976016
- Drug: PF-07976016
- Drug: [14C] PF-07976016
Primary outcome
what the primary-completion date above is the date OFTotal recovery of radioactivity expressed as a percent of total oral radioactive dose administered.
measured From dose (Day 1) and for up to 21 days thereafter
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed